A real-world experience with a thin-strut bioresorbable vascular scaffold system: a single-centre study

Our preliminary data suggest that the thin-strut sirolimus-eluting bioresorbable scaffold appears to be a clinically acceptable, safe, reliable and reproducible strategy to treat both <i>de novo</i> and in-stent restenotic coronary artery lesions. Long-term follow-up of a larger patient population is warranted.